Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Trial Profile

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Dec 2017 Planned primary completion date changed from 12 Jun 2017 to 6 Aug 2018.
    • 01 Dec 2017 Planned number of patients changed from 42 to 24.
    • 01 Dec 2017 Planned End Date changed from 6 Aug 2017 to 6 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top